Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AXIM BIOTECHNOLOGIES, INC.AXIM · Entity 9689 | Director · President and Director · 10% owner | January 30, 2024 | October 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AXIM BIOTECHNOLOGIES, INC.
Report date January 30, 2024 · Filed October 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,608,220 |
Reported balance
After 2024-01-30 transaction · row 1
1 source rowRow 1 · 2024-01-30 · Purchase · Acquired 1,086,216 · Balance 28,608,220 F1: Acquired from third party |
Filing footnotes · ownership attribution and instrument terms
F1: Acquired from third party
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2024 Filed Mar 19, 2024 19:39 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | GrantConvertible Note · Derivative | 7,837,500 | $156,750.00 Strike: $0.02 | $1,228,528,125,000.00 |
DisclosureSEC source: 0001096906-24-000524 · form4.xml · derivative · entry 1 Valencia Catalina · CIK 0001944813 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,837,500 Underlying: Common Stock · 7,837,500 shares Expires 2034-03-01 F1 · shares: Reporting Person acquired a convertible note, face value $156,750. The note is convertible into shares of the Issuer's common stock at a price of $0.02 per share for conversion into a total of 7,837,500 shares.. Read SEC document |
| January 30, 2024 Filed Oct 15, 2024 17:05 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | PurchaseCommon Stock | 1,086,216 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001096906-24-002004 · form4.xml · nonDerivative · entry 1 Valencia Catalina · CIK 0001944813 · Director · President and Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,608,220 F1 · price: Acquired from third party Read SEC document |
| August 24, 2022 Filed Aug 31, 2022 16:01 UTC | AXIM BIOTECHNOLOGIES, INC. AXIM · Entity 9689 | PurchaseCommon Stock | 3,861,004 | $0.03 | $100,000.00 |
DisclosureSEC source: 0001096906-22-002075 · form4.xml · nonDerivative · entry 1 Valencia Catalina · CIK 0001944813 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,661,004 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.